Its a funny old world

Interesting how the Novogen pre-clinical 'breakthrough' has been responded to the market, yet PXS has an even bigger opportunity with its SSAO and LOXL2 pipeline (SSAO will go to clinic in the new year to a NASH market worth $35 billion, 13 million cases in US and Europe alone) and yet the market cap sits below the cash backing?

But its nice to see what a well worded announcement will do to a small cap bio's share price.

Looking forward to seeing more action on bronchitol or SSAO partnering announcements over the coming weeks.

DYOR